Literature DB >> 8671660

LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice.

T Miyazaki1, A Dierich, C Benoist, D Mathis.   

Abstract

The product of the LAG-3 gene is a cell surface protein with significant homology to CD4. It has been suggested that it can serve as a functional equivalent of CD4 and account for the MHC class II-restricted responses which persist in CD4-deficient mice. To test this hypothesis, we have created CD4/LAG-3 double-deficient mice by successive homologous recombinations in embryonic stem cells. These animals turn out to be indistinguishable from CD4 single-deficient mice in their lymphocyte populations and responses that are controlled by MHC class II molecules. LAG-3 thus does not explain class II-restricted lymphocyte selection and function in the absence of CD4, strengthening the idea that these phenomena can occur independently of co-receptor signalling.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671660     DOI: 10.1093/intimm/8.5.725

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  14 in total

Review 1.  LAG-3 in Cancer Immunotherapy.

Authors:  Monica V Goldberg; Charles G Drake
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring.

Authors:  H Ghiasi; S Cai; G C Perng; A B Nesburn; S L Wechsler
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

Review 3.  Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.

Authors:  Christopher J Nirschl; Charles G Drake
Journal:  Clin Cancer Res       Date:  2013-07-18       Impact factor: 12.531

4.  LAG-3 regulates plasmacytoid dendritic cell homeostasis.

Authors:  Creg J Workman; Yao Wang; Karim C El Kasmi; Drew M Pardoll; Peter J Murray; Charles G Drake; Dario A A Vignali
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 5.  Melanoma: oncogenic drivers and the immune system.

Authors:  Niki Karachaliou; Sara Pilotto; Cristina Teixidó; Santiago Viteri; María González-Cao; Aldo Riso; Daniela Morales-Espinosa; Miguel Angel Molina; Imane Chaib; Mariacarmela Santarpia; Eduardo Richardet; Emilio Bria; Rafael Rosell
Journal:  Ann Transl Med       Date:  2015-10

Review 6.  Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies.

Authors:  Danuta J Herzyk; Helen G Haggerty
Journal:  AAPS J       Date:  2018-02-07       Impact factor: 4.009

Review 7.  Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.

Authors:  Simona Sivori; Paola Vacca; Genny Del Zotto; Enrico Munari; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Cell Mol Immunol       Date:  2019-02-18       Impact factor: 11.530

8.  LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.

Authors:  Ruea-Yea Huang; Cheryl Eppolito; Shashikant Lele; Protul Shrikant; Junko Matsuzaki; Kunle Odunsi
Journal:  Oncotarget       Date:  2015-09-29

9.  Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).

Authors:  Mario Martínez Soldevilla; Sandra Hervas; Helena Villanueva; Teresa Lozano; Obdulia Rabal; Julen Oyarzabal; Juan José Lasarte; Maurizio Bendandi; Susana Inoges; Ascensión López-Díaz de Cerio; Fernando Pastor
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

Review 10.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.